Left ventricular thrombi in malignancy: A therapeutic dilemma

Warfarin is the current standard of care for left ventricular thrombi (LVT).1,2 However, in the setting of malignancy, warfarin is of notoriously low efficacy. We highlight clinically useful data for maneuvering this catch-22 of LVT in malignancy, and expose the need for conclusive prospective studies.
Source: Heart and Lung - Category: Intensive Care Authors: Source Type: research